GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » Capex-to-Operating-Income

ReNeuron Group (LSE:RENE) Capex-to-Operating-Income : 0.00 (As of Sep. 2023)


View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

ReNeuron Group's Capital Expenditure for the six months ended in Sep. 2023 was £0.00 Mil. Its Operating Income for the six months ended in Sep. 2023 was £-3.30 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


ReNeuron Group Capex-to-Operating-Income Historical Data

The historical data trend for ReNeuron Group's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Capex-to-Operating-Income Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ReNeuron Group's Capex-to-Operating-Income

For the Biotechnology subindustry, ReNeuron Group's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReNeuron Group's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Capex-to-Operating-Income falls into.



ReNeuron Group Capex-to-Operating-Income Calculation

ReNeuron Group's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.22) / -7.115
=N/A

ReNeuron Group's Capex-to-Operating-Income for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -3.3
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReNeuron Group  (LSE:RENE) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


ReNeuron Group Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (LSE:RENE) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.

ReNeuron Group (LSE:RENE) Headlines